Member access

4-Traders Homepage  >  Shares  >  Nyse  >  AbbVie Inc    ABBV   US00287Y1091

ABBVIE INC (ABBV)

57
 SummaryQuotesChart AnalysisNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nyse
12/15/2014 12/16/2014 12/17/2014 12/18/2014 12/19/2014 Date
65.62(c) 65.25(c) 66.57(c) 67.92(c) 67.71(c) Last
7 231 014 8 545 063 5 934 879 7 184 735 12 461 241 Volume
+0.54% -0.56% +2.02% +2.03% -0.31% Change
More quotes
Company
AbbVie, Inc. is a research-based biopharmaceutical company.It engages in the discovery, development, manufacture and sale of a broad line of proprietary pharmaceutical products.The company's products are used to treat rheumatoid arthritis, psoriasis, Crohn's disease, HIV, cystic fibrosis... 
Sector
Pharmaceuticals
Calendar
01/13Ex-dividend day
More about the company
Surperformance© ratings of AbbVie Inc
Trading Rating : Investor Rating :
More Ratings
Chart ABBVIE INC
Duration : Period :
AbbVie Inc Technical Analysis Chart | ABBV | US00287Y1091 | 4-Traders
Full-screen chart
Financials ($)
Sales 2014 19 911 M
EBIT 2014 6 971 M
Net income 2014 4 642 M
Debt 2014 5 127 M
Yield 2014 2,49%
Sales 2015 22 932 M
EBIT 2015 9 073 M
Net income 2015 6 690 M
Debt 2015 4 160 M
Yield 2015 2,91%
PER 2014 27,08
PER 2015 15,62
EV / Sales 2014 5,68x
EV / Sales 2015 4,89x
Capitalization 107 893 M
More Financials
Latest news on ABBVIE INC
11h ago Fear factor fades as global M&A hits seven-year high
2d ago ABBVIE : Receives U.S. FDA Approval of VIEKIRA PAK(TM) (Ombitasvir/Paritaprevir/..
2d ago ABBVIE : FDA approves AbbVie combo hepatitis C treatment
4d ago ABBVIE : Reports from AbbVie Inc. Describe Recent Advances in Embryonic Research..
4d ago ABBVIE : New Crohn's Disease Findings from AbbVie Inc. Discussed (Long-term safe..
4d ago Shire considering bid for NPS Pharmaceuticals - Bloomberg
4d ago ABBVIE : Senators Baldwin and Coburn Applaud Commitment to Enhance Access to HIV..
6d ago GALAPAGOS : selects second component of its investigational cystic fibrosis comb..
More news
Sector news
4h ago MERCK : buys new-cancer-drug firm
11h ago Fear factor fades as global M&A hits seven-year high
1d ago AstraZeneca CEO says new Pfizer bid unlikely - Swedish daily DI
More sector news


Comments 
Advertisement
Technical analysis trends
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Technical analysis
Income Statement Evolution
More Financials
EPS Revisions
More Estimates Revisions
Dynamic quotes  
ON
| OFF